At a glance
ClinicalIndex Comparison Record- ✓Mild to moderate knee osteoarthritis confirmed by radiographic imaging.
- ✕Secondary knee osteoarthritis (OA due to underlying disease or prior injury).
- ✕Diseases other than osteoarthritis that could cause knee pain.
- ✕Any prior knee surgery or intra-articular injection.
- ✕Concurrent medications that potentially affect bone or cartilage of the knee joint.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee Osteoarthritis
In Brief
A Phase 2 clinical trial evaluating PG-530742, Placebo, and 3 other interventions for Osteoarthritis, Knee. Completed, enrolled 395 participants across 23 sites in 2 countries.
Detailed Summary
Matrix metalloproteinases (MMPs) have been implicated in the cartilage degradation. PG-530742 inhibits some MMPs, potentially limiting cartilage degradation and disease progression. This study will test the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.
Study Details
Timeline
Interventions
One 25 mg PG-530742 tablet, twice daily for for one year
One placebo tablet, twice daily for for one year
One 50 mg PG-530742 tablet, twice daily for for one year
100 mg PG-530742 tablet, twice a day for one year
200 mg PG-530742 tablet, twice a day for one year